Janice Bailey, Jason Acker and Louise St-Onge have joined the GlycoNet Board of Directors
Category: Network News
Tiny antibodies could help treat an aggressive type of breast cancer
GlycoNet researchers have developed specialized nanobodies that could enable the immune system to fight triple-negative breast cancer more effectively.
Nobel Prize in Chemistry shines light on glycomics
Congratulations to Drs. Carolyn Bertozzi and Morten Meldal whose groundbreaking work has opened doors in glycomics innovation.
GlycoNet Integrated Services awarded $10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund
Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.
GlycoNet researchers develop new chemical biological tools to monitor Parkinson’s disease
Researchers are a step closer to understanding how Parkinson’s disease develops and progresses.
GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
Engagement and collaboration in action at the 2022 Canadian Glycomics Symposium
Read some highlights from the 2022 Canadian Glycomics Symposium.
Enzymes linked with immune cell activity could hold key to better understanding inflammation
Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
Glycomics is writing the next chapter in bioinnovation
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.